Skip to search formSkip to main contentSkip to account menu

eprosartan

Known as: Éprosartan, (e)-2-Butyl-1-(P-carboxybenzyl)-alpha-2-thenylimidazole-5-acrylic acid, 2-Thiophenepropanoic acid, alpha-((2-butyl-1-((4- carboxyphenyl)methyl)-lH-imidazol-5-yl)methylene)-, (E)- 
A competitive and reversible angiotensin II receptor antagonist with anti-hypertensive property. Eprosartan blocks the binding of angiotensin II to… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
An 83-year-old woman with hypertension received the angiotensin-II receptor type 1 blocker (ARB) eprosartan for more than 10… 
Review
2008
Review
2008
Context Although evidence suggests that both angiotensin-receptor blockers (ARBs) and angiotensin-converting enzyme (ACE… 
Highly Cited
2005
Highly Cited
2005
Background and Purpose— In hypertensive stroke patients, for the same level of blood pressure control, eprosartan will be more… 
Highly Cited
2005
Highly Cited
2005
Angiotensin-converting enzyme (ACE)-2 is a newly described enzyme with antagonistic effects to those of the classical ACE (ACE-1… 
Highly Cited
2004
Highly Cited
2004
Background—Angiotensin type 1 receptor (AT1R) blockers (ARB) have been shown to reduce the incidence of type 2 diabetes mellitus… 
Highly Cited
2004
Highly Cited
2004
We evaluated the antihypertensive activity, glucose homeostasis and plasma lipid profile in patients with mild hypertension and…